Table 2.
Liraglutide clinical outcomes by baseline BMI at baseline and 6-month follow-up
| Clinical outcomes, mean (SD) | Baseline BMI, kg/m2 | |||||
|---|---|---|---|---|---|---|
| All | 25.0–29.9 | 30.0–34.9 | 35.0–39.9 | ≥40.0 | P value∆ | |
| A1C (N) | 1,649 | 186 | 454 | 440 | 569 | |
| Baseline A1C | 8.59 (1.36) | 8.58 (1.30) | 8.71 (1.47) | 8.58 (1.38) | 8.51 (1.26) | 0.12 |
| 6-month A1C | 7.65 (1.43)* | 7.63 (1.29)* | 7.70 (1.40)* | 7.59 (1.46)* | 7.67 (1.48)* | 0.71 |
| Absolute change in A1C from baseline | −0.94 (1.57)* | −0.95 (1.56)* | −1.02 (1.61)* | −0.99 (1.55) * | −0.84 (1.55)* | 0.30 |
| A1C ≤6.5% at 6 months | 20.6 | 18.3 | 20.9 | 21.1 | 20.6 | 0.87 |
| A1C <7.0% at 6 months | 39.5 | 38.2 | 37.0 | 40.9 | 41.0 | 0.54 |
| Weight (N) | 1,554 | 173 | 433 | 416 | 532 | |
| Baseline weight, kg | 109.6 (23.8) | 82.5 (10.2) | 95.0 (11.9) | 108.8 (13.9) | 131.0 (22.1) | <0.01 |
| 6-month weight, kg | 106.7 (23.5)* | 80.9 (10.8)* | 93.1 (12.8)* | 105.8 (14.5)* | 126.9 (22.4)* | <0.01 |
| Absolute change in weight from baseline, kg | −2.9 (5.7)* | −1.5 (4.8)* | −1.9 (4.2)* | −3.0 (4.8)* | −4.0 (7.3)* | <0.01 |
| Relative change in weight from baseline, % | −2.5 (5.7)* | −1.8 (5.8)* | −2.1 (4.4)* | −2.7 (4.4)* | −3.0 (6.1)* | <0.01 |
| TC (N) | 700 | 84 | 206 | 188 | 222 | |
| Baseline TC, mg/dL | 175.7 (43.0) | 176.7 (44.3) | 175.6 (43.7) | 177.9 (45.6) | 173.5 (39.8) | 0.75 |
| 6-month TC, mg/dL | 165.2 (40.1)* | 165.4 (39.5)* | 162.1 (40.3)* | 165.6 (42.4)* | 167.7 (38.3)* | 0.49 |
| Absolute change in TC from baseline, mg/dL | −10.4 (36.5)* | −11.3 (40.1)* | −13.5 (38.6)* | −12.2 (34.6)* | −5.8 (34.3)* | 0.14 |
| HDL (N) | 692 | 82 | 202 | 191 | 217 | |
| Baseline HDL, mg/dl | 41.8 (11.0) | 43.4 (12.8) | 42.1 (10.2) | 40.7 (10.9) | 41.9 (11.2) | 0.34 |
| 6-month HDL, mg/dl | 41.8 (11.3) | 44.9 (14.3)* | 42.2 (10.5) | 40.2 (10.9) | 41.7 (10.8) | <0.01 |
| Absolute change in HDL from baseline, mg/dL | −0.02 (6.6) | 1.5 (5.7)* | 0.07 (6.6) | −0.6 (6.5) | −0.2 (6.5) | 0.11 |
| SBP (N) | 1,549 | 172 | 430 | 411 | 536 | |
| Baseline SBP, mmHg | 129.9 (15.6) | 126.4 (14.7) | 128.9 (16.3) | 130.8 (15.5) | 131.2 (15.3) | <0.01 |
| 6-month SBP, mmHg | 127.0 (14.5)* | 123.8 (13.8)* | 126.5 (15.1)* | 127.0 (14.1)* | 128.4 (14.2)* | <0.01 |
| Absolute change in SBP from baseline, mmHg | −2.9 (16.5)* | −2.6 (15.6)* | −2.4 (16.8)* | −3.7 (15.8)* | −2.9(17.1)* | 0.67 |
| DBP (N) | 1,548 | 172 | 430 | 410 | 536 | |
| Baseline DBP, mmHg | 77.7 (9.8) | 76.2 (9.5) | 76.6 (9.9) | 77.9 (9.7) | 79.0 (9.7) | <0.01 |
| 6-month DBP, mmHg | 76.5 (9.6)* | 73.9 (8.7)* | 75.9 (9.9) | 77.0 (9.7) | 77.4 (9.4)* | <0.01 |
| Absolute change in DBP from baseline, mmHg | −1.26 (10.3)* | −2.3 (9.1)* | −0.7 (10.5) | −0.9 (9.9) | −1.6 (10.7)* | 0.28 |
Includes adults with type 2 diabetes with valid data at baseline and follow-up
DBP diastolic blood pressure, HDL high-density lipoprotein, SPB systolic blood pressure, TC total cholesterol
* Differences between baseline and 6 month follow-up values statistically significant (P < 0.05). P values were determined using paired t-test for continuous measures and McNemar’s test for categorical measures. ∆Statistical significance across BMI categories was determined through analysis of variance (ANOVA) for continuous variables and Chi-square test for categorical variables